CCDC102A Antibody

What are the key specifications of commercially available CCDC102A antibodies?

Based on the available research resources, CCDC102A antibodies are typically polyclonal rabbit antibodies that react with human and mouse species. Here is a comparison of two commercially available CCDC102A antibodies:

Why does the observed molecular weight of CCDC102A differ from the calculated weight?

The discrepancy between the observed molecular weight (72 kDa or 63-65 kDa, depending on the antibody) and the calculated molecular weight (approximately 62.6 kDa) is a common phenomenon in protein research that warrants methodological consideration. This difference typically results from post-translational modifications such as phosphorylation, glycosylation, or other chemical alterations that occur after protein synthesis. In the case of CCDC102A, this difference may be particularly relevant given its known phosphorylation by Nek2A at the onset of mitosis . Additionally, the coiled-coil domain structure can affect protein migration in SDS-PAGE, causing altered mobility compared to the predicted molecular weight based on amino acid sequence alone. When conducting Western blot analysis, researchers should be aware of this difference and consider it normal for CCDC102A detection . Experimental validation using positive controls like HeLa cell lysates can help establish the expected migration pattern in your specific experimental system.

What are the optimal conditions for Western blot analysis of CCDC102A?

For optimal Western blot analysis of CCDC102A, researchers should implement the following methodological approach:

• Sample preparation: Use cell lysates from appropriate cell lines known to express CCDC102A, such as HeLa or LOVO cells .

• Antibody dilution: Use a dilution range of 1:500 to 1:2000 of the primary antibody. The optimal dilution may vary depending on the specific antibody and sample type, so titration is recommended .

• Controls: Include positive controls (such as HeLa cell lysate) and negative controls (such as a blocking peptide competition assay) to validate specificity. As demonstrated in the validation images of commercial antibodies, the signal can be blocked with the synthesized peptide, confirming specificity .

• Expected molecular weight: Look for bands at approximately 63-72 kDa, keeping in mind that the observed molecular weight may differ from the calculated weight (62.6 kDa) due to post-translational modifications or the nature of coiled-coil proteins .

• Incubation conditions: Standard overnight incubation at 4°C for primary antibody is recommended, followed by appropriate secondary antibody incubation (typically 1-2 hours at room temperature).

• Detection method: Both chemiluminescence and fluorescence-based detection systems can be used, depending on the laboratory's available equipment and desired sensitivity.

How can researchers validate the specificity of CCDC102A antibody in their experimental system?

Validating antibody specificity is crucial for reliable research outcomes. For CCDC102A antibody, researchers should implement multiple validation strategies:

• Blocking peptide competition: Incubate the antibody with the immunizing peptide before application to the membrane. If the signal disappears or is significantly reduced, this confirms specificity. This approach has been demonstrated with commercial CCDC102A antibodies, where Western blot signals from LOVO and HepG2 cell lysates were blocked with the synthesized peptide .

• Knockdown/knockout validation: Use siRNA, shRNA, or CRISPR-Cas9 to reduce or eliminate CCDC102A expression in cells, then compare antibody staining patterns between control and knockdown/knockout samples. A specific antibody will show reduced or absent signal in the knockdown/knockout samples .

• Cross-reactivity testing: Test the antibody on samples from different species if cross-reactivity is claimed. While some CCDC102A antibodies are validated for both human and mouse reactivity, testing on your specific samples is recommended .

• Multiple antibody comparison: Use antibodies from different sources or those targeting different epitopes of CCDC102A. Concordant results increase confidence in specificity.

• Immunoprecipitation followed by mass spectrometry: This advanced approach can confirm that the antibody is capturing the intended protein.

• Recombinant expression: Overexpress tagged CCDC102A and confirm detection by both the CCDC102A antibody and a tag-specific antibody.

What immunofluorescence protocols are recommended for studying CCDC102A localization at the centrosome?

Given CCDC102A's role as a centrosomal protein with a barrel-like structure in the proximal regions of parent centrioles , proper immunofluorescence protocols are essential to visualize its precise subcellular localization:

• Cell fixation: Use 4% paraformaldehyde for 15 minutes at room temperature to preserve protein structure, followed by permeabilization with 0.2% Triton X-100 for 10 minutes.

• Blocking: Block with 3-5% BSA or normal serum (matching the species of the secondary antibody) for 1 hour at room temperature.

• Primary antibody: Dilute CCDC102A antibody appropriately (starting with manufacturer's recommendation) and incubate overnight at 4°C .

• Co-staining markers: For centrosome co-localization studies, include antibodies against established centrosomal markers such as:

  • γ-tubulin (general centrosome marker)

  • Centrin (centriole marker)

  • Cep192 and Cep152 (proteins that interact with CCDC102A at centrosomes)

  • C-Nap1 (centrosome cohesion protein that binds to CCDC102A)

• Secondary antibodies: Use fluorophore-conjugated secondary antibodies with minimal cross-reactivity. Choose fluorophores with distinct emission spectra when performing co-localization studies.

• Counterstaining: DAPI staining for nuclei visualization is recommended.

• Microscopy: Confocal microscopy is preferred for precise localization studies, as centrosomes are small structures requiring high-resolution imaging.

• Cell cycle analysis: Since CCDC102A is removed from centrosomes during mitosis (after Nek2A-mediated phosphorylation) , synchronizing cells or identifying cells in different cell cycle stages is important for comprehensive localization studies.

What are common issues encountered when using CCDC102A antibodies and how can they be resolved?

Researchers working with CCDC102A antibodies may encounter several technical challenges. Here are common issues and their methodological solutions:

• Weak or no signal in Western blot:

  • Increase antibody concentration (try 1:500 if 1:2000 doesn't work)

  • Extend primary antibody incubation time (overnight at 4°C)

  • Increase protein loading amount

  • Check expression levels in your cell line; HeLa and LOVO cells have confirmed expression

  • Verify transfer efficiency with Ponceau S staining

  • Use enhanced chemiluminescence (ECL) substrates with higher sensitivity

• Multiple bands or non-specific binding:

  • Increase blocking time or concentration (5% milk or BSA)

  • Optimize antibody dilution (try more dilute solutions)

  • Include 0.1% Tween-20 in wash buffers and antibody diluents

  • Use freshly prepared buffers

  • Perform a blocking peptide competition assay to identify the specific band

  • Consider the possibility of isoforms or post-translational modifications

• Inconsistent results across experiments:

  • Standardize lysate preparation methods

  • Avoid repeated freeze-thaw cycles of the antibody (aliquot upon receipt)

  • Maintain consistent incubation times and temperatures

  • Use the same positive control across experiments

• Background issues in immunofluorescence:

  • Increase blocking time (2 hours at room temperature)

  • Use different blocking agents (try normal serum instead of BSA)

  • Include 0.1-0.3% Triton X-100 in antibody dilution buffer

  • Increase washing steps (5 x 5 minutes)

  • Filter secondary antibodies before use

• Cell cycle-dependent detection issues:

  • Since CCDC102A localization changes during cell cycle (removed after Nek2A phosphorylation at mitosis onset) , synchronize cells or use cell cycle markers for accurate interpretation

  • Consider phosphatase inhibitors in lysis buffers to preserve phosphorylation states

How can researchers optimize immunoprecipitation protocols for CCDC102A interaction studies?

Immunoprecipitation (IP) is valuable for studying CCDC102A's interactions with proteins like C-Nap1, Cep192, and Cep152 . Here's an optimized protocol:

• Lysis buffer selection: Use a gentle lysis buffer to preserve protein-protein interactions:

  • 50 mM Tris-HCl (pH 7.4)

  • 150 mM NaCl

  • 1% NP-40 or 0.5% Triton X-100

  • 1 mM EDTA

  • Protease inhibitor cocktail

  • Phosphatase inhibitors (crucial for preserving CCDC102A phosphorylation states)

• Cell preparation:

  • For centrosome studies, consider synchronizing cells at specific cell cycle stages

  • Use approximately 1-2 × 10^7 cells per IP reaction

  • Lyse cells on ice for 30 minutes with gentle agitation

• Pre-clearing: Pre-clear lysate with Protein A/G beads for 1 hour at 4°C to reduce non-specific binding.

• Antibody binding:

  • Use 2-5 μg of CCDC102A antibody per IP reaction

  • Incubate with pre-cleared lysate overnight at 4°C with gentle rotation

  • Add 30-50 μl of Protein A/G beads and incubate for an additional 2-4 hours

• Washing: Perform 4-5 stringent washes with wash buffer (lysis buffer with reduced detergent concentration)

• Elution and analysis:

  • Elute with 2X Laemmli buffer at 95°C for 5 minutes

  • Analyze by Western blot for interacting partners (C-Nap1, Cep192, Cep152)

  • For mass spectrometry analysis, elute with a non-denaturing elution buffer

• Controls:

  • Include an isotype control antibody IP

  • Include a sample with blocking peptide competition

  • For critical interactions, perform reciprocal IP with antibodies against the interacting partner

What approaches should be used to study CCDC102A phosphorylation by Nek2A kinase?

Studying the phosphorylation of CCDC102A by Nek2A kinase requires specialized approaches :

• Phospho-specific antibody development: Generate antibodies against phosphorylated CCDC102A peptides containing the Nek2A target sites. This approach requires:

  • In silico prediction of potential Nek2A phosphorylation sites in CCDC102A

  • Synthesis of phosphopeptides containing these sites

  • Antibody production and validation against phosphorylated and non-phosphorylated controls

• In vitro kinase assays:

  • Express and purify recombinant CCDC102A (full-length or fragments)

  • Incubate with active recombinant Nek2A kinase and ATP

  • Detect phosphorylation by:

    • Radioactive [γ-32P]ATP incorporation

    • Phospho-specific antibodies

    • Mass spectrometry to identify specific phosphorylated residues

• Cell-based phosphorylation studies:

  • Synchronize cells at G2/M transition when Nek2A is most active

  • Treat cells with Nek2A inhibitors or deplete Nek2A using siRNA

  • Immunoprecipitate CCDC102A and probe with phospho-specific antibodies or pan-phospho antibodies (anti-phospho-Serine/Threonine)

  • Use phosphatase treatment as a negative control

• Phospho-mimetic and phospho-deficient mutants:

  • Create CCDC102A mutants where potential Nek2A phosphorylation sites are mutated to:

    • Alanine (phospho-deficient)

    • Glutamic acid or aspartic acid (phospho-mimetic)

  • Express these mutants in cells and analyze:

    • Centrosome localization patterns

    • Cell cycle progression

    • Interaction with centrosomal partners (C-Nap1, Cep192, Cep152)

How can CCDC102A antibodies be utilized to investigate centrosome abnormalities in cancer cells?

CCDC102A's role in preventing centrosome overduplication makes it a promising target for cancer research, as centrosome abnormalities are hallmarks of many cancers . Advanced research applications include:

• Comparative expression analysis:

  • Analyze CCDC102A expression levels across cancer cell lines and matched normal tissues using Western blot

  • Correlate expression levels with centrosome numbers and cancer aggressiveness

• High-resolution microscopy techniques:

  • Super-resolution microscopy to precisely localize CCDC102A within the centrosome structure

  • Live-cell imaging with fluorescently tagged CCDC102A to monitor dynamics during cell cycle progression in normal vs. cancer cells

• Functional studies in cancer models:

  • Deplete CCDC102A in normal cells to determine if this induces centrosome amplification and genomic instability

  • Restore CCDC102A expression in cancer cells with centrosome abnormalities to assess rescue effects

  • Correlate CCDC102A expression with sensitivity to anti-mitotic drugs

• Mutation analysis:

  • Screen cancer samples for mutations in CCDC102A

  • Create mutation-specific antibodies or use existing antibodies to detect expression or localization changes

• Biomarker potential assessment:

  • Evaluate CCDC102A as a prognostic or predictive biomarker in cancer tissues

  • Develop immunohistochemistry protocols for tissue microarrays to facilitate large-scale studies

What methodologies can be employed to study the interaction of CCDC102A with Cep192 and Cep152 in centrosome duplication control?

Given that CCDC102A prevents centrosome overduplication by restricting interactions between Cep192 and Cep152 , several advanced methodologies can be employed to study this regulatory mechanism:

• Proximity-based interaction assays:

  • BioID or TurboID: Fuse a biotin ligase to CCDC102A to biotinylate proximal proteins (Cep192, Cep152)

  • APEX2 proximity labeling: Similar approach using peroxidase-mediated labeling

  • FRET/BRET: Monitor real-time interactions between fluorescently tagged proteins

  • Proximity Ligation Assay (PLA): Visualize endogenous protein interactions at centrosomes

• Structure-function analysis:

  • Generate domain-specific antibodies against CCDC102A to map interaction domains

  • Create deletion mutants of CCDC102A and assess their ability to interact with Cep192 and Cep152

  • Use peptide arrays to identify specific binding motifs

• Quantitative interaction proteomics:

  • SILAC or TMT-labeled immunoprecipitation followed by mass spectrometry

  • Compare interaction profiles in different cell cycle stages

  • Assess how post-translational modifications affect interaction strength

• In vitro reconstitution:

  • Express and purify recombinant CCDC102A, Cep192, and Cep152

  • Perform in vitro binding assays (pull-down, surface plasmon resonance)

  • Attempt to reconstitute minimal interaction complexes

• Advanced imaging techniques:

  • Expansion microscopy to physically enlarge centrosome structures

  • Single-molecule tracking to monitor protein dynamics

  • Correlative light and electron microscopy (CLEM) to correlate protein locations with ultrastructural features

How can researchers investigate the role of CCDC102A in regulating centrosome cohesion through C-Nap1 recruitment?

CCDC102A regulates the centrosome linker by recruiting and binding C-Nap1, which is essential for centrosome cohesion . Advanced research approaches include:

• High-resolution spatiotemporal analysis:

  • Use structured illumination microscopy (SIM) to map the precise localization of CCDC102A and C-Nap1 at the centrosome

  • Perform time-lapse imaging throughout the cell cycle using fluorescently tagged proteins

  • Quantify colocalization coefficients at different cell cycle stages

• Interaction domain mapping:

  • Generate truncated versions of CCDC102A and C-Nap1

  • Perform co-immunoprecipitation or yeast two-hybrid assays to identify minimal interaction domains

  • Create peptide arrays of overlapping CCDC102A sequences to identify specific C-Nap1 binding motifs

• Functional perturbation studies:

  • Express dominant-negative fragments of CCDC102A that compete for C-Nap1 binding

  • Create CCDC102A mutants that cannot bind C-Nap1 and assess effects on centrosome cohesion

  • Use acute protein degradation systems (e.g., auxin-inducible degron) for temporal control of CCDC102A levels

• Centrosome cohesion assays:

  • Measure inter-centrosomal distance in cells with modified CCDC102A expression

  • Use centrosome splitting agents (e.g., nocodazole) and assess recovery kinetics

  • Develop quantitative assays for centrosome cohesion strength

• Regulation of the CCDC102A-C-Nap1 interaction:

  • Investigate how Nek2A-mediated phosphorylation of CCDC102A affects C-Nap1 binding

  • Identify other post-translational modifications that regulate this interaction

  • Study how cell cycle-dependent kinases and phosphatases modulate the interaction

How should researchers interpret discrepancies in CCDC102A antibody staining patterns across different cell types or experimental conditions?

Variations in CCDC102A antibody staining patterns may reflect genuine biological differences or technical artifacts. Here's how to approach such discrepancies systematically:

• Biological factors to consider:

  • Cell cycle stage variations: CCDC102A is removed from centrosomes after Nek2A-mediated phosphorylation at mitosis onset , so staining patterns will naturally differ between interphase and mitotic cells

  • Expression level differences: Baseline CCDC102A expression may vary across cell types

  • Post-translational modifications: Phosphorylation or other modifications may mask or expose epitopes

  • Protein interactions: Binding partners might compete with antibody recognition

  • Isoform expression: Different cell types might express different CCDC102A isoforms

• Technical factors to evaluate:

  • Fixation method: Different fixatives (PFA vs. methanol) can alter epitope accessibility

  • Permeabilization conditions: Over-permeabilization may extract proteins or reduce staining

  • Antibody concentration: Titration curves should be performed for each cell type

  • Detection method sensitivity: Fluorophore brightness and microscope settings affect detection

  • Batch-to-batch antibody variation: Polyclonal antibodies may show lot-to-lot differences

• Validation approaches:

  • Use multiple antibodies targeting different epitopes

  • Include knockdown/knockout controls for each cell type

  • Perform correlative studies with tagged CCDC102A expression

  • Compare results with published literature and databases

What statistical approaches are recommended for quantifying CCDC102A levels in centrosome duplication and cohesion studies?

• Quantification parameters:

  • Centrosome number per cell (for duplication studies)

  • Inter-centrosomal distance (for cohesion studies)

  • CCDC102A fluorescence intensity at centrosomes

  • Colocalization coefficients with interacting partners (Cep192, Cep152, C-Nap1)

  • Temporal dynamics measurements

• Sampling considerations:

  • Analyze sufficient cell numbers (typically >100 cells per condition)

  • Account for cell cycle distribution (use markers like DAPI intensity for DNA content)

  • Include multiple biological replicates (at least 3 independent experiments)

  • Consider heterogeneity within cell populations

• Statistical tests:

  • For comparing two conditions: Student's t-test or Mann-Whitney U test (non-parametric)

  • For multiple conditions: ANOVA with appropriate post-hoc tests (Tukey, Dunnett, etc.)

  • For correlation studies: Pearson's or Spearman's correlation coefficients

  • For frequency data: Chi-square or Fisher's exact test

• Advanced statistical approaches:

  • Mixed-effects models to account for experiment-to-experiment variation

  • Bayesian analysis for complex datasets

  • Machine learning for pattern recognition in imaging data

  • Survival analysis for time-to-event data (e.g., time to centrosome separation)

How can researchers integrate CCDC102A findings with broader data on centrosome biology and cell cycle regulation?

Contextualizing CCDC102A research within the larger field of centrosome biology requires strategic approaches:

• Pathway integration:

  • Position CCDC102A within known centrosome duplication pathways

  • Map interactions with established regulators (PLK4, SAS-6, STIL, etc.)

  • Identify feedback loops and regulatory networks

  • Compare phenotypes of CCDC102A disruption with other centrosomal gene perturbations

• Cell cycle context:

  • Correlate CCDC102A dynamics with cell cycle phases using synchronized cells

  • Integrate with CDK activity data

  • Compare regulation by mitotic kinases beyond Nek2A

  • Assess impact on checkpoint activation

• Multi-omics integration:

  • Correlate protein-level findings with transcriptomic data

  • Integrate phosphoproteomic data to identify regulatory sites

  • Use protein interaction databases to predict functional relationships

  • Apply network analysis tools to position CCDC102A in cellular signaling networks

• Evolutionary perspective:

  • Compare CCDC102A function across species

  • Identify conserved domains and motifs

  • Correlate evolutionary conservation with functional importance

  • Consider paralogs and their potential redundant functions

• Disease relevance:

  • Correlate CCDC102A abnormalities with known centrosome-related diseases

  • Examine cancer mutation databases for CCDC102A alterations

  • Consider potential roles in developmental disorders

  • Assess as a potential therapeutic target